News Releases

PR Newswire, San Diego, March 25, 2020 – Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Lisa...

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, announced today that Ivor Royston, M.D., the Company's President and CEO, will...

PR Newswire, San Diego, February 4, 2020 - Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that Dan...

PR Newswire, San Diego, December 8, 2019 - Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that its lead...

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will...

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast...

PR Newswire, San Diego, November 6, 2019 – Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that its lead...

PR Newswire, San Diego, October 28, 2019 – Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced the closing of a Series D Preferred...

SAN DIEGO, Oct. 14, 2019 /PRNewswire/ – Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced today that Ivor Royston, MD, President and...

PR Newswire, San Diego, August 1, 2019 – Viracta Therapeutics, Inc. announced today that it has appointed Dan Chevallard as Chief Financial Officer and Xiaohu Deng, Ph.D. as Senior Vice...